---
title: "Xtandi (enzalutamide), all indications: Pharmacology questions"
description: "Pharmacology questions on Xtandi (enzalutamide) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Xtandi work (mechanism of action)? How is Xtandi metabolized? How long does Xtandi stay in your system (half-life)? What are the inactive ingredients in Xtandi? 4 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/xtandi/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xtandi (enzalutamide), all indications: Pharmacology questions

Manufacturer: Astellas Pharma US, Inc.; Pfizer Inc.  
Prescribing information: [Xtandi](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf)  
Indication pages: [Castration-resistant prostate cancer](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer)

## Mechanism

<a id="xtandi-mechanism"></a>

### How does Xtandi work (mechanism of action)?

> “XTANDI is an androgen receptor inhibitor that acts on multiple steps of the androgen receptor signaling pathway within the tumor cell<sup>1</sup>”

Source: [XTANDI: XTANDI® (enzalutamide) | Mechanism of Action, captured 2026-11-13](https://www.xtandihcp.com/about-xtandi/mechanism-of-action#:~:text=XTANDI%20is%20an%20androgen%20receptor,signaling%20pathway%20within%20the%20tumor)

> “Enzalutamide is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway. 
> Enzalutamide has been shown to competitively inhibit androgen binding to androgen receptors; and consequently, inhibits 
> nuclear translocation of androgen receptors and their interaction with DNA. A major metabolite, N-desmethyl 
> enzalutamide, exhibited similar in vitro activity to enzalutamide. Enzalutamide decreased proliferation and induced cell 
> death of prostate cancer cells in vitro, and decreased tumor volume in a mouse prostate cancer xenograft model.”

Source: [XTANDI: Prescribing information, page 16, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=16)

## Pharmacokinetics

<a id="xtandi-metabolism"></a>

### How is Xtandi metabolized?

> “Enzalutamide is primarily eliminated by hepatic metabolism.”

Source: [XTANDI: Prescribing information, page 17, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=17)

> “Enzalutamide is metabolized by CYP2C8 and CYP3A4. CYP2C8 is primarily responsible for the formation of the active 
> metabolite (N-desmethyl enzalutamide). Carboxylesterase 1 metabolizes N-desmethyl enzalutamide and enzalutamide to 
> the inactive carboxylic acid metabolite.”

Source: [XTANDI: Prescribing information, page 17, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=17)

<a id="xtandi-half-life"></a>

### How long does Xtandi stay in your system (half-life)?

> “The mean terminal 
> half-life (t1/2) for enzalutamide after a single oral dose is 5.8 days (2.8 to 10.2 days). The mean terminal t1/2 for 
> N-desmethyl enzalutamide is approximately 7.8 to 8.6 days.”

Source: [XTANDI: Prescribing information, page 17, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=17)

> “Enzalutamide achieves steady-state by Day 28 and its AUC accumulates approximately 8.3-fold relative to a single dose.”

Source: [XTANDI: Prescribing information, page 17, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=17)

## Components

<a id="xtandi-inactive-ingredients"></a>

### What are the inactive ingredients in Xtandi?

> “XTANDI is available as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of 
> enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl 
> polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, 
> purified water, titanium dioxide, and black iron oxide. 
> XTANDI is also available as film-coated tablets for oral administration. Each tablet contains 40 mg or 80 mg of 
> enzalutamide. The inactive ingredients are hypromellose acetate succinate, microcrystalline cellulose, colloidal silicon 
> dioxide, croscarmellose sodium, and magnesium stearate. The tablet film-coat contains hypromellose, talc, polyethylene 
> glycol, titanium dioxide, and ferric oxide.”

Source: [XTANDI: Prescribing information, page 16, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=16)

## Related pages
- [Medical information: Xtandi (enzalutamide): All indications](https://www.evicenter.com/medical-information/xtandi)
- [Indication](https://www.evicenter.com/medical-information/xtandi/indication)
- [Safety](https://www.evicenter.com/medical-information/xtandi/safety)
- [Specific populations](https://www.evicenter.com/medical-information/xtandi/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/xtandi/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/xtandi/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/xtandi/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/xtandi/access-and-coverage)
